Cost-effectiveness of universal MRSA screening on admission to surgery  by Murthy, A. et al.
Cost-effectiveness of universal MRSA screening on admission to surgery
A. Murthy1,2, G. De Angelis1, D. Pittet1, J. Schrenzel3, I. Uckay4 and S. Harbarth1
1) Infection Control Program, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland, 2) Johns Hopkins Bloomberg School of Public
Health, Baltimore, MD, USA, 3) Microbiology Laboratory, University of Geneva Hospitals and Faculty of Medicine, Geneva and 4) Department of Surgery,
University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland
Abstract
Policy-makers have recommended universal screening to reduce nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection.
Risk proﬁling of MRSA carriers and rapid PCR tests are now available, yet cost-effectiveness data are limited. The present study
assessed the cost-effectiveness of universal PCR screening on admission to surgery. A decision analysis model from the hospital per-
spective compared costs and the probability of any MRSA infection across three strategies: (i) PCR screening; (ii) screening for risk fac-
tors (prior hospitalization or antibiotic use) combined with pre-emptive isolation and contact precautions pending chromogenic agar
results; and (iii) no screening. Clinical data were taken from studies at a Swiss teaching hospital as well as from published literature.
Costs were derived from hospital accounting systems. Compared to no screening, the PCR strategy resulted in higher costs (CHF
10 503 vs. 10 358) but a lower infection probability (0.0041 vs. 0.0088), producing a base-case incremental cost-effectiveness ratio of
CHF 30 784 per MRSA infection avoided. The risk factor strategy was more costly yet less effective than PCR, although, after varying
epidemiologic inputs, the costs and effects of both screening strategies were similar. Sensitivity analyses suggested that on-admission
prevalence of MRSA carriage predicts cost-effectiveness, alongside the probability of cross-transmission, and the costs of MRSA infec-
tion, screening and contact precautions. Although reducing the risk of MRSA infection, universal PCR screening is not strongly cost-
effective at our centre. However, local epidemiology plays a critical role. Settings with a higher prevalence of MRSA colonization may
ﬁnd universal screening cost-effective and, in some cases, cost-saving.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is among
the leading pathogens responsible for hospital-acquired infec-
tions [1,2]. Approximately 80–95% of MRSA carriers are
asymptomatic and can thus serve as a ‘silent’ reservoir for
transmission [3,4]. As a result, experts and policy-makers
have called for universal screening at hospital admission to
detect carriers and reduce nosocomial MRSA infection [5].
Yet universal MRSA screening represents a signiﬁcant cost
burden for hospitals and remains controversial given the
number of patients placed in isolation and the risk of misclas-
siﬁcation [6]. Moreover, recent studies offer conﬂicting
results regarding the efﬁcacy of universal screening using
rapid PCR tests [7–11]. A recent large study investigating
on-admission screening combined with implementation of
contact isolation and decolonization treatment showed no
reduction in nosocomial MRSA infection [8]. Another ran-
domized study with higher baseline MRSA infection rates
also failed to show a reduction when comparing rapid
screening with conventional cultures [9]. By contrast, other
recent studies of universal rapid screening on admission
showed a decrease in MRSA acquisition or infection [7,10],
suggesting that study design, setting-speciﬁc factors and local
MRSA epidemiology affect the observed ability of rapid
screening to reduce infection [8].
Few studies have examined the cost implications of imple-
menting MRSA screening programmes [10,12–14]. The deci-
sion to implement an MRSA screening programme requires
signiﬁcant efforts related to laboratory capacity and behav-
iour change, among other costly components. Even where
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE 10.1111/j.1469-0691.2010.03220.x
studies of screening ﬁnd unclear effects on MRSA infection,
economic analyses are still beneﬁcial by characterizing the
potential economic costs and beneﬁts. The present study
aimed to assess the cost-effectiveness of universal PCR
screening in surgery.
Materials and Methods
Patient algorithm, analysis design and decision model
The economic analysis used data from a large, prospective
cohort study conducted at the surgical department of the
University of Geneva Hospital (HUG) in Switzerland. A com-
plete description of the cross-over study design, patient pop-
ulation, microbiologic studies and surveillance methods has
been reported elsewhere [8].
Using data from this study, a decision analytic Markov
model was constructed to compare the direct costs and
probability of any clinical MRSA infection across three con-
trol strategies: (i) PCR-based screening; (ii) screening for
MRSA risk factors with pre-emptive isolation and contact
precautions pending conﬁrmatory chromogenic agar test
results; and (iii) standard surgical admission without MRSA
screening on admission.
Screening based on risk proﬁling and subsequent pre-emp-
tive isolation was not evaluated in the cohort study. How-
ever, recent studies have evaluated various risk factors for
MRSA carriage [15,16], leading to the development of easily
modiﬁable risk scoring systems in surgical patients [17].
When combined with pre-emptive isolation of patients await-
ing conﬁrmatory culture results, the use of risk factor
screening could lead to signiﬁcant reductions in nosocomial
MRSA transmission and infection [18,19]. Consequently, we
included a risk factor alternative in the cost-effectiveness
analysis using data from published studies that have identiﬁed
recent hospitalization and exposure to antibiotic therapy as
signiﬁcant and sensitive predictors of MRSA carriage on
admission [2,16,20–23].
When awaiting the results of PCR (strategy 1), patients
remain in inpatient wards where no pre-emptive measures
are implemented. Patients with a positive PCR test (true posi-
tives and false positives) undergo infection control measures
for the remainder of the analysis period. These measures are
deﬁned as topical decolonization therapy (nasal mupirocin and
chlorhexidine washing), contact precautions (gloves, gowns,
notiﬁcation signs) and physical isolation (single room or
physical barriers), in line with clinical practice at our centre.
Patients identiﬁed as MRSA carriers via risk-proﬁling
(strategy 2) immediately receive the same standard control
measures until conﬁrmatory culture results (using chromo-
genic agar) are negative for MRSA. Therefore, the predictive
value of this strategy is a function of the performance of
both the two-variable risk factor screen and the conﬁrma-
tory chromogenic agar.
When awaiting the results of PCR or conﬁrmatory culture
(strategies 1 and 2), MRSA carriers may develop a clinical
infection, have a spontaneous loss of carriage, or cross-trans-
mit to a MRSA-free patient who may then develop clinical
infection. Rates of progression from carriage to infection and
spontaneous loss of carriage are taken from clinical studies
performed at our centre and from published data [24–26].
The rate of cross-transmission from carriers to noncarriers
is assumed to be 20% in the base case analysis, whereas the
effect of alternative transmission rates is explored in sensitiv-
ity analyses.
Identiﬁed carriers undergoing standard infection control
measures may also face the same event risks described
above. However, progression from carriage to clinical infec-
tion and cross-transmission are reduced in this instance by
the efﬁcacy of decolonization therapy and standard infection
control measures, respectively. Data on the efﬁcacy of
decolonization and infection control precautions were taken
from clinical trials conducted at our centre and those in the
published literature [27,28].
To account for differences in the turnaround time (TAT)
of PCR and culture tests, the analysis applies the probability
of events per hour and uses the test performance of PCR
and culture to allow for the accrual of costs and effects asso-
ciated with false-positive and false-negative results. Table 1
summarizes the data used to estimate effectiveness.
Cost evaluation
The time horizon for the analysis was the period of hospital-
ization and the perspective was that of the hospital adminis-
trator. Costs were extracted from our hospital’s cost
accounting systems [29] that aggregate the variable and ﬁxed
cost components of patient care by date of service. Addi-
tionally, interviews were conducted with infection control
staff and informatics units to estimate costs of consumables
and conﬁrm the clinical algorithm in the decision analysis.
Actual costs were used instead of charges to obtain a more
accurate estimate of ﬁnancial burden [30]. All costs were
computed in 2006 Swiss Francs (CHF).
The costs of PCR and agar screening included test materi-
als, laboratory staff and overheads. Staff costs for testing
were estimated by allocating the salary costs of the full-time
equivalent laboratory technicians required during the study
period across the number of tests conducted to determine
the unit cost per test. Capital costs for PCR equipment and
depreciation were not included because PCR was purchased
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prior to the start of our study and used widely by other
departments. The costs of infection control measures
included protection materials, decolonization therapy and
staff time.
Costs associated with MRSA infection were estimated as a
function of excess length of hospital stay (LOS) attributable
to infection and the cost per bed-day. The excess LOS
among patients in the original cohort study was derived from
an analysis using time-dependent and multivariate methods
[31,32]. The cost per bed-day derived from our centre’s
accounting system is based on the total expenditure divided
by the total produced activity and included labour and over-
head.
An incremental analysis was performed to derive the
incremental cost-effectiveness ratio, or additional cost per
MRSA infection avoided compared to the next effective
strategy. To assess the uncertainty in our model, univariate
sensitivity analyses were conducted. All modelling was per-
formed using Treeage Pro 2008 (TreeAge Software, Inc.,
Williamstown, MA, USA). Table 2 summarizes the cost
estimates used in the analysis.
Results
The baseline prevalence of MRSA carriage on admission was
estimated to be 5.1% from the active surveillance period of
our study. The estimated median TAT of the rapid PCR and
chromogenic agar tests was 22.5 and 28 h, respectively. Dur-
ing the period of our cohort study, the total cost per surgi-
cal bed-day was estimated to be CHF 1658 (± 202). The
cost per MRSA infection was 8292 CHF based on the excess
LOS attributable to infection.
Table 3 shows the results of the incremental analysis.
Compared to standard surgical admission without screening
(strategy 3), universal screening with rapid PCR (strategy 1)
resulted in higher costs (CHF 10 503 vs. 10 358) but a lower
infection probability (0.0041 vs. 0.0088) over the mean LOS
in our cohort study.
Compared to standard surgical admission without
screening (strategy 3), the hypothetical strategy of screen-
ing for MRSA risk factors plus pre-emptive precautions
TABLE 1. Epidemiological input
variables for cost-effectiveness
analysis
Model variable
Values
Point
estimate
Range used in
sensitivity analyses References
Probability of MRSA infection in patient
with nasal carriage (per hour)
0.00051 ±20% [8]
Efﬁcacy of decolonization treatment (mupirocin 2%) 0.90 0.30–1.0 [28]
Probability of MRSA carriage on admission 0.051 0.01–0.10 [8]
Probability of spontaneous loss of MRSA
carriage (per hour)
0.0001125 ±20% [25]
Probability of cross-transmission from colonized
to un-colonized patient (per hour)
0.008 ±20% Baseline assumption
Reduction in cross-transmission due to infection
control procedures (contact precautions, isolation)
0.5000 ±0.20 Baseline assumption
Sensitivity of two-factor risk score (strategy 2) 0.61 0.46–0.75 [20]
Speciﬁcity of two-factor risk score (strategy 2) 0.50 0.46–0.54 [20]
Sensitivity of the rapid PCR test 0.96 0.93–0.99 [8]
Speciﬁcity of the rapid PCR test 0.91 0.86–0.97 [8]
Sensitivity of the chromogenic agar testa 0.83 0.78–0.89 HUG
Speciﬁcity of the chromogenic agar testa 0.98 0.95–0.99 HUG
Median turnaround time of rapid PCR (h) 22.5 12.2–28.2 [8]
Median turnaround time of chromogenic agar (h) 28 ±4 HUG
Modelled exposure time in hospital (h) 150 SD (28.8) [8]
MRSA, methicillin-resistant Staphylococcus aureus; HUG, University of Geneva Hospitals.
aChromogenic agar performance at 24 h.
TABLE 2. Health care resource use and cost variables for
cost-effectiveness analysis
Model variable
Values
Point
estimate
Range used in
sensitivity
analyses
Incremental cost of MRSA infection
as a result of excess LOSa
CHF 8292 CHF 4975–11 608
Cost of decolonization treatment,
mupirocin 2%b
CHF 18.50 ±25%
Incremental cost per day of
infection control
(contact precautions) for
suspected carriersc
CHF 182 ±25%
Cost of rapid PCR screeningd CHF 41.36 ±25%
Cost of standard chromogenic
agar cultured
CHF 18.63 ±25%
Cost per surgical bed-day during
the study period
CHF 1658 SD CHF 202
All costs are expressed in 2006 Swiss Francs (CHF).
MRSA, methicillin-resistant Staphylococcus aureus; LOS, length of hospital stay.
aBased on 5 ± 2 day estimate from time-dependent, multivariate analyses.
bPharmacy acquisition cost at the University of Geneva Hospitals.
cIncludes gloves, gowns, notiﬁcation signs, and other consumables.
dIncludes all test components and laboratory staff costs.
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(strategy 2) also resulted in higher costs (CHF 10 511 vs.
10 358) and a lower infection probability (0.0057 vs.
0.0088). However, compared to the rapid PCR screen
(strategy 1), the risk factor screen (strategy 2) is more
costly but less effective, and is therefore dominated by the
rapid PCR screen.
The incremental cost per infection avoided between the
rapid PCR and standard admissions without screening was
CHF 30 784. Notably, the total costs of the two on-admis-
sion screening strategies were higher than not screening,
suggesting that the costs avoided by a reduction in MRSA
infection did not completely offset the costs associated with
screening at our centre.
Sensitivity analyses were conducted to assess the impact
of key input variables (Table 4). When comparing the three
scenarios, the prevalence of colonization on admission is a
predictor of cost-effectiveness. When the prevalence of
MRSA carriage on admission decreases from that observed
at our centre, PCR becomes less cost-effective (Fig. 1). By
contrast, higher prevalence improves the cost-effectiveness
and moves PCR toward cost-neutrality compared to admis-
sion without screening. However, at extremely high values,
the incremental cost of rapid PCR increases modestly.
Changes in the results obtained were observed when altering
the probability of cross-transmission, the efﬁcacy of decolo-
nization and contact precautions, and the costs of infection
and rapid screening (Table 4).
Discussion
Studies have examined the burden of MRSA [33], the cost
and budget impact associated with MRSA control [13,34],
and the direct costs of MRSA infection [35]. The present
study is unique by focusing on universal PCR screening on
admission for surgical patients using appropriate costing
methods [29,30] as well as data from a large clinical trial [8].
Effectiveness was measured as the number of MRSA infec-
tions avoided rather than surrogates such as time-to-notiﬁca-
tion, with the aim of capturing the most relevant clinical and
economic factors.
Our analysis suggests that, compared to surgical admis-
sions without screening, universal PCR is marginally more
costly and reduces infection risk, yielding a cost per infection
avoided of approximately CHF 31 000. Given the size and
scope of the infection control programme at our centre, the
use of universal rapid screening in surgery would unlikely be
deemed cost-effective. The relatively low rate of MRSA
infection, successful hand hygiene efforts and high compliance
among staff with infection control procedures reduce the
added value of improved carrier identiﬁcation at our hospital
[8]. By contrast, a recent study assessing the cost-effective-
ness of preoperative MRSA testing among vascular patients
[36] found such testing to be cost-effective. However, that
study was not focused on the use of rapid PCR technology
and did not examine the effect of TAT of testing. It also
reported quality-adjusted life years, yet this approach may
not be appropriate for hospital administrators with responsi-
bility for setting infection control priorities.
The inﬂuence of key input variables on the cost-effective-
ness ratio in our analysis is in line with clinical expectations
(Table 4). A potential explanation for the slightly worsening
cost-effectiveness of PCR at very high prevalence (Fig. 1)
could be that the proportion of all MRSA infections avoided
as a result of PCR begins to decline because of cross-trans-
mission occurring during the TAT of PCR.
Improving the diagnostic accuracy of the PCR test improves
the cost-effectiveness of this strategy compared to no screen-
ing. Improving the diagnostic performance of the risk factor or
conﬁrmatory chromogenic agar screens improves the cost-
effectiveness of that strategy relative to PCR.
Reducing the TAT of PCR improves its cost-effectiveness
compared to no screening, suggesting that newer bed-side
PCR screening technologies could further prevent cross-
infection. In the absence of a faster PCR test, measures
taken pre-emptively when awaiting test results could reduce
infection risk, although care should be taken to limit harm
and expenses associated with wrongful isolation of patients.
TABLE 3. Incremental cost-effectiveness analysis of rapid methicillin-resistant Staphylococcus aureus (MRSA) screening on
admission to surgery
Strategy
Modelled
cost (CHF)
Incremental
cost (CHF)
Decision analysis
infection probability
Incremental
effects
Cost-effectiveness
ratio
Incremental
cost-effectiveness (ICER)
No MRSA screening 10 358.46 – 0.0088 – 1 183 637.86
Universal rapid PCR screening 10 502.53 144.07 0.0041 0.0047 2 581 048.81 CHF 30 784
Risk factor screening 10 511.04 8.51 0.0057 0.0016 1 843 826.63 (Dominated)
All costs are expressed in 2006 Swiss Francs (CHF).
ICER, incremental cost-effectiveness ratio, or the difference in costs divided by the difference in effects. The dominated strategy (risk factor screening) is one that has higher
costs but lower beneﬁts than a competing alternative (rapid PCR screening) and would therefore not be rationally selected.
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TABLE 4. Sensitivity analysis: variables affecting cost-effectiveness results
Input variable
Input effect on ICER Input variable range
Low High Low High
(A) ICER, rapid PCR vs. surgical admission without screening
Cost in ward when under isolation (per hour), CHF 25K 100K 57.51 95.85
Probability a patient has MRSA on admission 148K 18K 0.01 0.10
Speciﬁcity of rapid PCR 42K 20K 0.86 0.97
Probability of infection among nasal carriers (per hour) 36K 28K 0.00041 0.00061
Efﬁcacy of isolation and contact precautions at reducing transmission 36K 29K 0.40 0.60
Cost of MRSA infection (based on attributable length of stay), CHF 35K 28K 4975 11608
Probability of cross-transmission in normal ward (per hr) 34K 28K 0.0067 0.0099
Efﬁcacy of decolonization at reducing risk of colonization
progressing to infection
54K 30K 0.30 1.0
Cost of rapid PCR test, CHF 29K 34K 31.02 51.7
Sensitivity of rapid PCR 31K 29K 0.93 0.99
Turnaround time of rapid PCR (h) 15K 33K 12 28
(B) ICER, rapid PCR vs. risk factor screening
Cost in ward while under isolation (per hour), CHF )40K 28K 57.51 95.85
Speciﬁcity of rapid PCR )41K 24K 0.86 0.97
Probability a patient has MRSA on admission )47K )1K 0.01 0.10
Speciﬁcity of chromogenic agar )14K 3K 0.95 0.99
Speciﬁcity of two-factor risk score )13K 1K 0.46 0.54
Cost of rapid PCR test, CHF )12K 1K 31.02 51.7
Sensitivity of two-factor risk score )14K )2K 0.46 0.75
Turnaround time of chromogenic agar (h) )1K )10K 24 32
Cost of MRSA infection (based on attributable length of stay), CHF )9K )2K 4975 11608
Cost of decolonization, CHF )8K )4K 14 24
Cost of a standard screen, CHF )7K )4K 14 23.3
Turnaround time of rapid PCR (h) )12K )3K 12 28
Sensitivity of rapid PCR )7K )5K 0.93 0.99
Sensitivity of chromogenic agar )6K )5K 0.78 0.89
C) ICER, risk factor vs. standard surgical admission without screening
Cost in ward while under isolation (per hour), CHF )74K 173K 57.51 95.85
Probability a patient has MRSA on admission 28K 255K 0.01 0.1
Efﬁcacy of decolonization at reducing risk of
colonization progressing to infection
85K 47K 0.30 1.0
Sensitivity of two-factor risk score 64K 42K 0.46 0.75
Probability of infection among nasal carriers (per hour) 56K 45K 0.00041 0.00061
Efﬁcacy of isolation and contact precautions at reducing transmission 56K 45K 0.40 0.60
Probability of cross-transmission in normal ward (per hour) 55K 46K 0.0067 0.0099
Speciﬁcity of chromogenic agar 54K 46K 0.95 0.99
Speciﬁcity of two-factor risk score 54K 46K 0.46 0.54
Cost of MRSA infection (based on attributable length of stay), CHF 53K 47K 4975 11608
Turnaround time of chromogenic agar (h) 48K 52K 24 32
Sensitivity of chromogenic agar 51K 49K 0.78 0.89
Cost of decolonization, CHF 49K 51K 14 24
Cost of a standard screen, CHF 49K 51K 14 23.3
Negative incremental cost-effectiveness ratios (ICERs) indicate ﬁrst alternative is cost-saving. All costs are expressed in 2006 Swiss Francs (CHF).
MRSA, methicillin-resistent Staphylococcus aureus; PCR, polymerase chain reaction.
Chromogenic agar performance measured at 24 h.
Cost-effectiveness of universal rapid PCR screening and
prevalence of MRSA carriage on admission
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FIG. 1. Sensitivity analysis: cost-effective-
ness of universal rapid PCR screening and
prevalence of methicillin-resistant Staphylo-
coccus aureus (MRSA) carriage on admis-
sion. Figure compares rapid PCR to
standard surgical admission without scree-
ning. All costs are expressed in 2006 Swiss
Francs (CHF).
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Reducing the TAT of chromogenic agar had a similar effect
on the cost-effectiveness of the risk factor strategy.
Increasing the efﬁcacy of decolonization or pre-emptive
control measures improves the cost-effectiveness of the PCR
strategy, suggesting that the beneﬁts of improved carrier
identiﬁcation are reduced in the absence of appropriate
interventions for those identiﬁed. Speciﬁcally, early identiﬁca-
tion yields fewer beneﬁts when the efﬁcacy of decolonization
treatment decreases. At a level of 0.30, the cost-effectiveness
of PCR declined substantially. Varying the risk of cross-trans-
mission among unidentiﬁed carriers also affects the results,
with higher transmission improving the cost-effectiveness of
the PCR strategy. Centres with high MRSA endemicity or
low adherence to basic infection control procedures such as
hand hygiene may ﬁnd rapid universal screening to be more
cost-effective than at our centre.
The cost of an infection as well as the cost of the PCR test
inﬂuences the results as expected. In settings where excess
LOS attributable to infection is higher than we estimate, PCR
would be more cost-effective because avoided infections offer
larger economic beneﬁts. Previous studies estimated the
excess LOS attributable to MRSA surgical site infections [37],
bacteraemia [35] and intensive care unit infections [26] with
results in the range 2–8 days. On the basis of time-dependent
and multivariate techniques, we used an estimate of
5 ± 2 days. Attributing cost-related outcomes to infection
requires consideration of bias from multiple sources [32] and
further studies with robust estimation methods are needed.
Although we only examined PCR and risk factor approaches,
there are other screening algorithms available for consider-
ation. Indeed, other studies evaluated risk proﬁles with addi-
tional factors [17] and alternative PCR technologies [9–11,34]
with varying scenarios of conﬁrmatory testing and pre-emptive
measures, all of which inﬂuence MRSA transmission and costs.
Given the varying strategies available, there is need for
additional research on the economics of MRSA control.
We chose the perspective of the hospital administrator.
MRSA infection also has signiﬁcant effects on community
care, and the overall burden of MRSA is signiﬁcant [38].
Analyses with broader perspectives could help shape national
policies [32,36]. However, the cost of implementing universal
screening involves the acquisition of material, labour time
and the re-organization of operations. These costs are gen-
erally borne directly by hospitals.
It may be possible that reductions in MRSA infection as a
result of either PCR or risk factor strategies could outweigh
the costs of these interventions, depending on local costs
and epidemiology. Results may differ outside of surgical
departments. However, our analysis suggests that cost-neu-
trality or cost reductions with screening are not guaranteed.
Moreover, the economic beneﬁts of avoided infections are
largely ﬁxed and not avoidable in the short-term [39].
Administrators should not interpret the beneﬁts of avoided
infection as cash savings, but rather as resources that could
be used more productively. Additionally, the costs of infec-
tion also include lost revenue as a result of excess bed-days.
In the absence of an established willingness-to-pay for
avoided infection, decision-makers should consider cost-
effectiveness results in light of local resource availability.
Universal screening remains an important infection control
strategy for consideration. Yet, to our knowledge, there are
few assessments of MRSA screening costs relative to clini-
cally relevant effects. Not surprisingly, a recent health tech-
nology assessment of MRSA screening that included a
systematic review of the literature called for further research
on the costs and effects of MRSA control programmes [40].
Universal PCR screening may offer a cost-effective option
to reduce MRSA infection. However, local epidemiology,
costs, and infection control practices play an important role
and should be considered in any evaluation of screening.
Given the complexities of selecting an appropriate screening
strategy, further research on the cost-effectiveness of MRSA
infection control is required.
Acknowledgements
We are grateful to E. Safran, C. Fankhauser, J. Christenson
and P. Garnerin for their contribution to this project. Fur-
thermore, we thank the personnel of the Infection Control
Program and the Departments of Surgery and Anesthesiol-
ogy for their full support and help.
Transparency Declaration
The authors would like to acknowledge the ﬁnancial support
of The Geneva University Hospitals (CI 70897 and CI
13003) and the Swiss National Science Foundation (grant
4049-40-106294/1). J.S. is developer and patent holder of the
rapid MRSA test mentioned in the article. S.H. received con-
sulting fees and speaker honoraria from 3M, BioMerieux,
Destiny Pharma and Roche Diagnostics.
References
1. Klevens RM, Edwards JR, Tenover FC et al. Changes in the epidemi-
ology of methicillin-resistance Staphylococcus aureus in intensive care
units in US hospitals, 1992–2003. Clin Infect Dis 2006; 42: 389–391.
1752 Clinical Microbiology and Infection, Volume 16 Number 12, December 2010 CMI
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1747–1753
2. Harbarth S. Control of endemic MRSA: recent advances and future
challenges. Clin Microbiol Infect 2006; 12: 1154–1162.
3. Harbarth S, Martin Y, Rohner P, Henry N, Auckenthaler R, Pittet D.
Effect of delayed infection control measures on a hospital outbreak of
methicillin-resistant Staphylococcus aureus. J Hosp Infect 2000; 46: 43–49.
4. Huang SS, Platt R. Risk of MRSA infection after previous infection or
colonization. Clin Infect Dis 2003; 36: 281–285.
5. Weber SG, Huang SS, Oriola S et al. Legislative mandates for use of
active surveillance cultures to screen for methicillin-resistant Staphylo-
coccus aureus and vancomycin-resistant enterococci: position state-
ment from the Joint SHEA and APIC Task Force. Am J Infect Control
2007; 35: 73–85.
6. Diekema DJ, Edmund MB. Look before you leap: active surveillance for
multi-drug resistant organisms. Clin Infect Dis 2007; 44: 1101–1107.
7. Robicsek A, Beaumont JL, Paule SM et al. Universal surveillance for
methicillin-resistant Staphylococcus aureus in 3 afﬁliated hospitals. Ann
Intern Med 2008; 148: 409–418.
8. Harbarth S, Fankhauser C, Schrenzel J et al. Universal screening for
methicillin-resistant Staphylococcus aureus at hospital admission and
nosocomial infection in surgical patients. JAMA 2008; 299: 1149–1157.
9. Jeyaratnam D, Whitty CL, Phillips K et al. Impact of rapid screening
tests on acquisition of methicillin-resistant Staphylococcus aureus: clus-
ter randomized crossover trial. BMJ 2008; 336: 927–930.
10. Keshtgar MR, Khalili A, Coen PG et al. Impact of rapid molecular
screening for methicillin-resistant Staphylococcus aureus in surgical
wards. Br J Surg 2008; 95: 381–386.
11. Hardy K, Price C, Szczepura A et al. Reduction in the rate of MRSA
acquisition in surgical wards by rapid screening for colonization: a
prospective, cross-over study. Clin Microbiol Infect 2010; 16: 333–339.
12. Conterno LO, Shymanski J, Ramotar K et al. Real-time polymerase
chain reaction detection of MRSA: impact on nosocomial transmis-
sion and costs. Infect Control Hosp Epidemiol 2007; 28: 1134–1141.
13. Noskin GA, Rubin RJ, Schentag JJ et al. Budget impact analysis of
rapid screening for Staphylococcus aureus colonization among patients
undergoing elective surgery in US hospitals. Infect Control Hosp
Epidemiol 2008; 29: 16–24.
14. Buhlmann M, Bogli-Stuber K, Droz S et al. Rapid screening for car-
riage of MRSA by PCR and associated costs. J Clin Microbiol 2008; 46:
2151–2154.
15. Marshall C, Wolfe R, Kossmann T et al. Risk factors for acquisition
of methicillin-resistant Staphylococcus aureus (MRSA) by trauma
patients in the intensive care unit. J Hosp Infect 2004; 57: 245–252.
16. Lucet JC, Chevret S, Durand-Zaleski I et al. Prevalence and risk fac-
tors for carriage of methicillin-resistant Staphylococcus aureus at
admission to the intensive care unit: results of a multicenter study.
Arch Intern Med 2003; 163: 181–188.
17. Harbarth S, Sax H, Uckay I et al. A predictive model for identifying
surgical patients at risk of MRSA carriage on admission. J Amer Coll
Surg 2008; 207: 683–689.
18. Cooper BS, Stone SP, Kibbler CC et al. Isolation measures in the
hospital management of MRSA: systematic review of the literature.
BMJ 2004; 329: 533–540.
19. Bootsma MC, Diekmann O, Bonten MJ. Controlling methicillin-resis-
tant Staphylococcus aureus: quantifying the effects of interventions and
rapid diagnostic testing. Proc Natl Acad Sci USA 2006; 103: 5620–5625.
20. Furuno JP, McGregor J, Harris A et al. Identifying groups at high risk
for carriage of antibiotic-resistant bacteria. Arch Intern Med 2006; 166:
580–585.
21. Troillet N, Carmeli Y, Samore MH et al. Carriage of methicillin-resis-
tant Staphylococcus aureus at hospital admission. Infect Control Hosp
Epidemiol 1998; 19: 181–185.
22. Rezende NA, Blumberg HM, Metzger BS et al. Risk factors for methi-
cillin-resistance among patients with Staphylococcus aureus bacteremia
at the time of hospital admission. Am J Med Sci 2002; 323: 117–123.
23. Tacconelli E, Venkataraman L, De Girolami PC et al. Methicillin-resis-
tant Staphylococcus aureus bacteraemia diagnosed at hospital admis-
sion: distinguishing between community-acquired versus healthcare-
associated strains. J Antimicrob Chemother 2004; 53: 474–479.
24. Coello R, Glynn JR, Gaspar C, Picazo JJ, Fereres J. Risk factors for
developing clinical infection with methicillin-resistant Staphylococcus
aureus (MRSA) amongst hospital patients initially only colonized with
MRSA. J Hosp Infect 1997; 37: 39–46.
25. Cooper BS, Stone SP, Kibbler CC et al. Systematic review of isolation
policies in the hospital management of MRSA: a review of the litera-
ture with epidemiological and economic modeling. Health Technol
Assess 2003; 7: 1–194.
26. Chaix C, Durand-Zaleski I, Alberti C et al. Control of endemic
methicillin-resistant Staphylococcus aureus: a cost-beneﬁt analysis in an
intensive care unit. JAMA 1999; 282: 1745–1751.
27. Harbarth S, Dharan S, Liassine N et al. Randomized, placebo-con-
trolled, double-blind trial to evaluate the efﬁcacy of mupirocin for
eradicating carriage of MRSA. Antimicrob Agents Chemother 1999; 43:
1412–1416.
28. Ammerlaan HSM, Klutmans JAJW, Wertheim HFL et al. Eradication
of MRSA carriage: a systematic review. Clin Infect Dis 2009; 48: 922–
930.
29. Borst F, Appel R, Baud R et al. Happy Birthday DIOGENE: a hospital
information system born 20 years ago. Int J Med Inform 1999; 54:
157–167.
30. Graves N, Harbarth S, Beyersmann J, Barnet A, Halton K, Cooper B.
Estimating the cost of health care-associated infections: mind your p’s
and q’s. Clin Infect Dis 2010; 50: 1017–1021.
31. Beyersmann J, Gastmeier P, Wolkewitz M et al. An easy mathematical
proof showed that time-dependent bias inevitably leads to biased
effect estimation. J Clin Epidemiol 2008; 61: 1216–1221.
32. Graves N, Weinhold D, Tong E et al. Effect of healthcare acquired
infection on length of hospital stay and cost. Infect Control Hosp
Epidemiol 2007; 28: 261–264.
33. Noskin GA, Rubin RJ, Schentaj JJ et al. The burden of Staphylococcus
aureus infections on hospitals in the US: an analysis of the 2000 and
2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005;
165: 1756–1761.
34. Shrestha NK, Shermock KM, Gordon SM et al. Predictive value and
cost-effectiveness analysis of rapid polymerase chain reaction for pre-
operative detection of nasal carriage of Staphylococcus aureus. Infect
Control Hosp Epidemiol 2003; 24: 327–333.
35. Cosgrove SE, Qi Y, Kaye KS et al. The impact of methicillin resis-
tance in Staphylococcus aureus bacteremia on patient outcomes: mor-
tality, length of stay, and hospital charges. Infect Control Hosp
Epidemiol 2005; 27: 994–995.
36. Lee BY, Tsui BY, Bailey RR et al. Should vascular surgery patients be
screened preoperatively for methicillin-resistant Staphylococcus aureus?
Infect Control Hosp Epidemiol 2009; 30: 1158–1165.
37. Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and eco-
nomic outcomes attributable to methicillin resistance among patients
with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;
36: 592–598.
38. Plowman R, Graves N, Grifﬁn MA et al. The rate and cost of hospital
acquired infections occurring in patients admitted to selected special-
ties of a district general hospital in England, and the national burden
imposed. J Hosp Infect 2001; 47: 198–209.
39. Roberts RR, Frutos PW, Ciavarella GC et al. Distribution of ﬁxed vs
variable costs of hospital care. JAMA 1999; 281: 644–649.
40. Ritchie K, Bradbury I, Craig J, et al. The clinical and cost-effectiveness
of screening for MRSA. NHS Quality Improvement Scotland. 2007
October; HTA Report 9.
CMI Murthy et al. Cost-effectiveness of MRSA screening 1753
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1747–1753
